

S 1341

A bill to amend the Internal Revenue Code of 1986 to expand human clinical trials qualifying for the orphan drug credit, and for other purposes.

Congress: 107 (2001–2003, Ended)

Chamber: Senate

Policy Area: Taxation

Introduced: Aug 2, 2001

Current Status: Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S8763)

Latest Action: Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S8763) (Aug 2, 2001)

Official Text: <https://www.congress.gov/bill/107th-congress/senate-bill/1341>

Sponsor

Name: Sen. Hatch, Orrin G. [R-UT]

Party: Republican • **State:** UT • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Jeffords, James M. [I-VT]	I · VT		Aug 2, 2001
Sen. Kennedy, Edward M. [D-MA]	D · MA		Aug 2, 2001
Sen. Kerry, John F. [D-MA]	D · MA		Aug 3, 2001

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Aug 2, 2001

Subjects & Policy Tags

Policy Area:

Taxation

Related Bills

No related bills are listed.

Summary (as of Aug 2, 2001)

Amends the Internal Revenue Code of 1986, with respect to the research tax credit for clinical testing expenses for certain drugs for rare diseases or conditions (orphan drugs), to change the qualifying date of such testing from the date of designation as an orphan drug by the Food and Drug Administration to the date such a designation is applied for.

Amends the Federal Food, Drug, and Cosmetic Act to instruct the Secretary of Health and Human Services to publish monthly in the Federal Register notice of requests and approvals concerning designation of orphan drugs.

Actions Timeline

- **Aug 2, 2001:** Introduced in Senate
- **Aug 2, 2001:** Sponsor introductory remarks on measure. (CR 8/3/2001 S8762-8763)
- **Aug 2, 2001:** Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S8763)